Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer.

NPJ Breast Cancer · 2023 · PMC10491615 · PMID 37684290

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

They did not meet their primary objective of PFS improvement in pretreated HR + /HER2− ABC over ET of physician’s choice 42 , 43 , although a numerical trend suggested greater benefit in the presence of ESR1 mutations.

also in 268 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.